Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A rare combination of CYP2C9*3/*3 and VKORC1 1639AA in a patient had myxoma and thromboembolism.

Son KH, Lee SI, Choi CH, Park KY, Park CH.

Ann Thorac Surg. 2019 Sep 11. pii: S0003-4975(19)31361-X. doi: 10.1016/j.athoracsur.2019.07.072. [Epub ahead of print]

PMID:
31520636
2.

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Molden E, Okkenhaug C, Ekker Solberg E.

Eur J Clin Pharmacol. 2010 May;66(5):525-30. doi: 10.1007/s00228-010-0813-6. Epub 2010 Mar 31.

PMID:
20354686
3.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
4.

Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.

Aomori T, Obayashi K, Fujita Y, Araki T, Nakamura K, Nakamura T, Kurabayashi M, Yamamoto K.

Pharmazie. 2011 Mar;66(3):222-5.

PMID:
21553655
5.

Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, Mehta R, Doctor T, Shah VK, Saranath D.

J Assoc Physicians India. 2012 Dec;60:34-8.

PMID:
23781667
6.

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.

Zhang J, Chen Z, Chen C.

Meta Gene. 2016 Jul 5;9:197-209. doi: 10.1016/j.mgene.2016.07.002. eCollection 2016 Sep. Review.

7.

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.

Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ.

J Clin Pharm Ther. 2012 Apr;37(2):232-6. doi: 10.1111/j.1365-2710.2011.01262.x. Epub 2011 Apr 20.

PMID:
21507031
8.

Genetic and clinical determinants influencing warfarin dosing in children with heart disease.

Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ.

Pediatr Cardiol. 2013 Apr;34(4):984-90. doi: 10.1007/s00246-012-0592-1. Epub 2012 Nov 25.

PMID:
23183958
9.

The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.

Bedewy AML, Sheweita SA, Mostafa MH, Kandil LS.

Indian J Hematol Blood Transfus. 2018 Apr;34(2):328-336. doi: 10.1007/s12288-016-0725-4. Epub 2016 Sep 27. Erratum in: Indian J Hematol Blood Transfus. 2018 Apr;34(2):337.

10.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
11.

Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).

Nakagita K, Wada K, Mukai Y, Uno T, Nishino R, Matsuda S, Takenaka H, Terakawa N, Oita A, Takada M.

Eur J Clin Pharmacol. 2018 Jul;74(7):885-894. doi: 10.1007/s00228-018-2483-8. Epub 2018 May 21.

PMID:
29781049
12.

Reviews of Selected Pharmacogenetic Tests for Non-Cancer and Cancer Conditions [Internet].

Raman G, Trikalinos TA, Zintzaras E, Kitsios G, Ziogas D, Ip S, Lau J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Nov 12.

13.

Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.

Lu Y, Yang J, Zhang H, Yang J.

Clin Pharmacokinet. 2013 Jul;52(7):567-81. doi: 10.1007/s40262-013-0054-9.

PMID:
23515956
14.

Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring.

Aomori T, Fujita Y, Obayashi K, Sato H, Kiyotani K, Nakamura K, Nakamura T, Yamamoto K.

J Clin Pharm Ther. 2014 Jun;39(3):319-21. doi: 10.1111/jcpt.12135. Epub 2014 Feb 25.

PMID:
24612117
15.

Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.

Ghozlan MF, Foad DA, Darwish YW, Saad AA.

Blood Coagul Fibrinolysis. 2015 Jul;26(5):499-504. doi: 10.1097/MBC.0000000000000272.

PMID:
25699611
16.

Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.

An SH, Lee KE, Chang BC, Gwak HS.

J Clin Pharm Ther. 2014 Jun;39(3):314-8. doi: 10.1111/jcpt.12143. Epub 2014 Mar 6.

PMID:
24602049
17.

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Ye C, Jin H, Zhang R, Sun Y, Wang Z, Sun W, Sun W, Peng Q, Liu R, Huang Y.

J Int Med Res. 2014 Feb;42(1):67-76. doi: 10.1177/0300060513499094. Epub 2013 Nov 28.

PMID:
24287930
18.

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA.

Clin Pharmacol Ther. 2006 Apr;79(4):291-302. Epub 2006 Feb 28.

PMID:
16580898
19.

Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.

Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.

Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.

PMID:
23839801
20.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3.

PMID:
19077919

Supplemental Content

Support Center